196 related articles for article (PubMed ID: 23326369)
1. Nuclear legumain activity in colorectal cancer.
Haugen MH; Johansen HT; Pettersen SJ; Solberg R; Brix K; Flatmark K; Maelandsmo GM
PLoS One; 2013; 8(1):e52980. PubMed ID: 23326369
[TBL] [Abstract][Full Text] [Related]
2. Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells.
Tamhane T; Lllukkumbura R; Lu S; Maelandsmo GM; Haugen MH; Brix K
Biochimie; 2016 Mar; 122():208-18. PubMed ID: 26343556
[TBL] [Abstract][Full Text] [Related]
3. Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges.
Brix K; McInnes J; Al-Hashimi A; Rehders M; Tamhane T; Haugen MH
Protoplasma; 2015 May; 252(3):755-74. PubMed ID: 25398648
[TBL] [Abstract][Full Text] [Related]
4. Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer.
Murthy RV; Arbman G; Gao J; Roodman GD; Sun XF
Clin Cancer Res; 2005 Mar; 11(6):2293-9. PubMed ID: 15788679
[TBL] [Abstract][Full Text] [Related]
5. High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting.
Haugen MH; Boye K; Nesland JM; Pettersen SJ; Egeland EV; Tamhane T; Brix K; Maelandsmo GM; Flatmark K
Eur J Cancer; 2015 Jan; 51(1):9-17. PubMed ID: 25466510
[TBL] [Abstract][Full Text] [Related]
6. Mammalian legumain - A lysosomal cysteine protease with extracellular functions?
Lunde NN; Bosnjak T; Solberg R; Johansen HT
Biochimie; 2019 Nov; 166():77-83. PubMed ID: 31181234
[TBL] [Abstract][Full Text] [Related]
7. A protease-responsive fluorescent probe for sensitive imaging of legumain activity in living tumor cells.
Li X; Liu Q; Ye S; Wang S; Li K; Lv G; Peng Y; Qiu L; Lin J
Chem Biol Drug Des; 2019 Aug; 94(2):1494-1503. PubMed ID: 31002467
[TBL] [Abstract][Full Text] [Related]
8. MiRNA-3978 regulates peritoneal gastric cancer metastasis by targeting legumain.
Zhang Y; Wu YY; Jiang JN; Liu XS; Ji FJ; Fang XD
Oncotarget; 2016 Dec; 7(50):83223-83230. PubMed ID: 27793040
[TBL] [Abstract][Full Text] [Related]
9. Esomeprazole inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis.
Zhao T; Liu Y; Hao Y; Zhang W; Tao L; Wang D; Li Y; Liu Z; McKenzie EA; Zhao Q; Diao A
Invest New Drugs; 2021 Apr; 39(2):337-347. PubMed ID: 32978718
[TBL] [Abstract][Full Text] [Related]
10. Low-level internalization of cystatin E/M affects legumain activity and migration of melanoma cells.
Wallin H; Apelqvist J; Andersson F; Ekström U; Abrahamson M
J Biol Chem; 2017 Sep; 292(35):14413-14424. PubMed ID: 28630039
[TBL] [Abstract][Full Text] [Related]
11. Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M.
Smith R; Johansen HT; Nilsen H; Haugen MH; Pettersen SJ; Mælandsmo GM; Abrahamson M; Solberg R
Biochimie; 2012 Dec; 94(12):2590-9. PubMed ID: 22902879
[TBL] [Abstract][Full Text] [Related]
12. Cystatin C properties crucial for uptake and inhibition of intracellular target enzymes.
Wallin H; Abrahamson M; Ekström U
J Biol Chem; 2013 Jun; 288(23):17019-17029. PubMed ID: 23629651
[TBL] [Abstract][Full Text] [Related]
13. Legumain Functions as a Transient TrkB Sheddase.
Holzner C; Böttinger K; Blöchl C; Huber CG; Dahms SO; Dall E; Brandstetter H
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982466
[TBL] [Abstract][Full Text] [Related]
14. Structure and function of legumain in health and disease.
Dall E; Brandstetter H
Biochimie; 2016 Mar; 122():126-50. PubMed ID: 26403494
[TBL] [Abstract][Full Text] [Related]
15. Legumain correlates with neuroblastoma differentiation and can be used in prodrug design.
Zhang M; Jiang Z; Chen S; Wu Z; Chen K; Wu Y
Chem Biol Drug Des; 2018 Feb; 91(2):534-544. PubMed ID: 28994241
[TBL] [Abstract][Full Text] [Related]
16. The Mammalian Cysteine Protease Legumain in Health and Disease.
Solberg R; Lunde NN; Forbord KM; Okla M; Kassem M; Jafari A
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555634
[TBL] [Abstract][Full Text] [Related]
17. Glycosylation is important for legumain localization and processing to active forms but not for cystatin E/M inhibitory functions.
Lunde NN; Haugen MH; Bodin Larsen KB; Damgaard I; Pettersen SJ; Kasem R; Rut W; Drag M; Poreba M; Johansen HT; Solberg R
Biochimie; 2017 Aug; 139():27-37. PubMed ID: 28528272
[TBL] [Abstract][Full Text] [Related]
18. Tailor-made legumain/pH dual-responsive doxorubicin prodrug-embedded nanoparticles for efficient anticancer drug delivery and in situ monitoring of drug release.
Li Y; Niu Y; Zhu J; Gao C; Xu Q; He Z; Chen D; Xu M; Liu Y
Nanoscale; 2020 Jan; 12(4):2673-2685. PubMed ID: 31942900
[TBL] [Abstract][Full Text] [Related]
19. Nuclear cysteine cathepsin variants in thyroid carcinoma cells.
Tedelind S; Poliakova K; Valeta A; Hunegnaw R; Yemanaberhan EL; Heldin NE; Kurebayashi J; Weber E; Kopitar-Jerala N; Turk B; Bogyo M; Brix K
Biol Chem; 2010 Aug; 391(8):923-35. PubMed ID: 20536394
[TBL] [Abstract][Full Text] [Related]
20. Cloning and expression of mouse legumain, a lysosomal endopeptidase.
Chen JM; Dando PM; Stevens RA; Fortunato M; Barrett AJ
Biochem J; 1998 Oct; 335 ( Pt 1)(Pt 1):111-7. PubMed ID: 9742219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
